Recent Advances in Research on Parkinson Disease: Synuclein and Parkin

Neurologist

Volumn 10, Issue 2, 2004, Pages 75-81

  Burke, Robert E ^a,b  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Parkin; Proteasome; Synuclein; Ubiquitin

Indexed keywords

ALANINE; CELL PROTEIN; PARKIN; SYNUCLEIN; THREONINE; UBIQUITIN PROTEIN LIGASE;

AMINO ACID SUBSTITUTION; AUTOSOMAL RECESSIVE DISORDER; CELL INCLUSION; DOPAMINERGIC NERVE CELL; FAMILIAL DISEASE; GENE DELETION; GENE MUTATION; HUMAN; LEWY BODY; MEDICAL RESEARCH; OXIDATION; PARKINSON DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; CYSTEINE ENDOPEPTIDASES; HUMANS; MULTIENZYME COMPLEXES; MUTATION; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; SYNAPTIC VESICLES; SYNUCLEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 1642342857     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000117822.90759.83     Document Type: Review

References (58)

1. Ward CD, Duvoisin RC, Ince SE, et al. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology. 1983;33:815-824.
2. Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson's disease: a reappraisal. Mov Disord. 1990;5:187-194.
3. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281:341-346.
4. Langston JW, Ballard PA, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.
5. Golbe LI, Di Iorio G, Bonavita V, et al. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol. 1990;27:276-282.
6. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 1996;274:1197-1199.
7. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the a-synuclein gene identified in families with Parkinson's Disease. Science. 1997;276:2045-2047.
8. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease [letter]. Nat Genet. 1998;18:106-108.
9. Spillantini MG, Schmidt ML, Lee VMY, et al. a-Synuclein in Lewy bodies. Nature. 1997;388:839-840.
10. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8:2804-2815.
11. Maroteaux L, Scheller RH. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Mol Br Res. 1991;11: 335-343.
12. Culvenor JG, McLean CA, Cutt S, et al. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol. 1999;155:1173-1181.
13. George JM, Jin H, Woods WS, et al. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 1995;15:361-372.
14. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-Ab component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14:467-475.
15. Irizarry MC, Kim TW, McNamara M, et al. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J Neuropath Exp Neurol. 1996;55:889-895.
16. Jensen PH, Nielsen MS, Jakes R, et al. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem. 1998;273:26292-26294.
17. Murphy DD, Rueter SM, Trojanowski JQ, et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci. 2000;20:3214-3220.
18. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239-252.
19. Dauer WT, Kholodilov N, Vila M, et al. Resistance of a-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 2002;in press:
20. Iwai A, Yoshimoto M, Masliah E, et al. Non-Ab component of Alzheimer's Disease amyloid (NAC) is amyloidogenic. Biochemistry. 1995; 34:10139-10145.
21. Han H, Weinreb PH, Lansbury PTJ. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol. 1995;2:163-169.
22. Hashimoto M, Hsu LJ, Sisk A, et al. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 1998;799:301-306.
23. El-Agnaf OM, Jakes R, Curran MD, et al. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett. 1998;440:67-70.
24. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4:1318-1320.
25. Narhi L, Wood SJ, Steavenson S, et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem. 1999; 274:9843-9846.
26. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem. 1999;274:7619-7622.
27. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann Neurol. 1992;32:804-812.
28. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985-989.
29. Souza JM, Giasson BI, Chen Q, et al. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem. 2000;275:18344-18349.
30. Paik SR, Shin HJ, Lee JH. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch Biochem Biophys. 2000;378:269-277.
31. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404:394-398.
32. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265-1269.
33. Giasson BI, Duda JE, Quinn SM, et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521-533.
34. Lee MK, Stirling W, Xu Y, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002;99:8968-8973.
35. Conway KA, Rochet JC, Bieganski RM, et al. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001;294:1346-1349.
36. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392: 605-608.
37. Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology. 1996;47:160-166.
38. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology. 1994;44:437-441.
39. Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol. 1998;44:935-941.
40. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet. 1999;8:567-574.
41. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med. 2000;342:1560-1567.
42. Wickner S, Maurizi MR, Gottesman S. Posttranslational quality control: folding, refolding, and degrading proteins. Science. 1999;286:1888-1893.
43. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 1998;17:7151-7160.
44. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem. 1999;274:22123-22126.
45. Shimura H, Hattori N, Kubo S, et al. Familial parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25: 302-305.
46. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem. 2000;275:35661-35664.
47. Imai Y, Soda M, Inoue H, et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 2001;105:891-902.
48. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 1999;13:1211-1233.
49. Patil C, Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. Curr Opin Cell Biol. 2001;13:349-355.
50. Zinszner H, Kuroda M, Wang X, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998;12:982-995.
51. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 2001;293:263-269.
52. Engelender S, Kaminsky Z, Guo X, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet. 1999;22:110-114.
53. Chung KKK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the a-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat Med. 2001;7:1144-1150.
54. Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol. 2000;47: 521-523.
55. Stefanis L, Larsen KE, Rideout HJ, et al. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001;21:9549-9560.
56. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 2001; 10:919-926.
57. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256-259.
58. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.